Drug Trial Radar · NCT04752371
A Study to Evaluate Camoteskimab in Participants With Still's Disease
Last checked: Nov 19, 2026Latest source record: Aug 23, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
5
Actual
Start
Mar 25, 2021
Primary completion
May 24, 2022
Study completion May 24, 2022
Sponsor
- Lead sponsor
- Apollo Therapeutics LtdIndustry
- Sponsor type
- Industry
- First posted
- Feb 12, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of the study is to evaluate the safety and tolerability of Camoteskimab in participants with Still's Disease.
Conditions
- Adult Onset Still's Disease
Interventions
Camoteskimab (CERC-007, AVTX-007, AEVI-007)Drug
Intravenous (IV) Infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of AEsTime frame: Baseline to Week 24
- Incidence of Clinically Significant Changes from Baseline in Vital SignsTime frame: Baseline to Week 24
- Incidence of Clinically Significant Changes from Baseline in Clinical Laboratory ResultsTime frame: Baseline to Week 24
Locations
11 sites in 4 countries. Site status is shown where the registry gives one.
Sponsor Investigative Site
Gainesville, Florida
Sponsor Investigative Site
Ann Arbor, Michigan
Sponsor Investigative Site
Ghent, Oost-Vlaanderen, Belgium
Sponsor Investigative Site
Elblag, Poland
Sponsor Investigative Site
Pomorskie, Poland
Sponsor Investigative Site
Poznan, Poland
Sponsor Investigative Site
Poznan, Poland
Sponsor Investigative Site
Kyiv, Ukraine
Sponsor Investigative Site
Poltava, Ukraine
Sponsor Investigative Site
Ternopil, Ukraine
Sponsor Investigative Site
Vinnitsa, Ukraine
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.